Welcome to our dedicated page for STERIS plc SEC filings (Ticker: STE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
STERIS plc filings document material events for an Ireland-incorporated operating company with ordinary shares traded as STE on the New York Stock Exchange. Recent Form 8-K reports cover results of operations and financial condition, attached earnings releases, director appointments and retirements, officer transition arrangements, and compensation-related amendments.
The filing record also identifies STERIS securities registered under Section 12(b), including ordinary shares and NYSE-listed senior notes due 2031 and 2051. These disclosures frame the company’s capital structure, governance actions, executive-compensation matters, and periodic operating-result announcements for its infection-prevention and life sciences business.
STERIS plc held its 2026 Annual General Meeting of Shareholders on July 31, 2026. There were 97,457,680 ordinary shares outstanding and entitled to vote, and holders of 89,909,204 shares, or 92.25%, were present in person or by proxy, constituting a quorum. Effective upon completion of the meeting, the size of the Board of Directors was set at nine members.
Shareholders cast votes for nine director nominees, including Dr. Esther M. Alegria, Pierre Boulud, Daniel A. Carestio, Cynthia L. Feldmann, Christopher S. Holland, Paul E. Martin, Dr. Nirav R. Shah, Louis A. Shapiro and Dr. Mohsen M. Sohi, with each nominee receiving tens of millions of votes in favor. The results also detail votes for and against several additional management proposals, with broker non-votes where applicable.
STERIS plc reports that Director Pierre Boulud, whose election and the expansion of the Board from nine to ten members were previously disclosed, has received his initial committee assignments. Effective July 31, 2026, he was appointed to the Board’s Audit Committee and its Compliance and Technology Committee.
The company notes that no other changes were made to the matters previously reported regarding the Board’s composition or Mr. Boulud’s role.
STERIS plc reported fiscal 2027 first-quarter results and outlined a new chemistries consolidation plan. Revenue rose 7% to $1.5 billion, with constant currency organic growth of 6%. Net income attributable to shareholders was $200.1 million and diluted EPS was $2.04, up from $1.79. Adjusted EPS increased to $2.59 from $2.34.
Healthcare revenue grew 8% to $1.05 billion, Applied Sterilization Technologies 6% to $297.6 million, and Life Sciences 9% to $146.7 million, with operating income higher in all three segments. Operating cash flow was $367.1 million and free cash flow $279.6 million, lower than the prior year mainly because working capital contributed less, partly offset by higher net income.
The company announced a targeted restructuring linked to a new formulated chemistries Center of Excellence in North Carolina. STERIS expects total pre-tax restructuring charges of $55–$70 million, including $40–$50 million of cash costs and $15–$20 million of non-cash charges, with completion anticipated during fiscal 2030; these will be excluded from adjusted earnings. The company reaffirmed its fiscal 2027 outlook for 7–8% reported revenue growth and adjusted EPS of $11.10–$11.30, while increasing planned capital expenditures to about $450 million and lowering expected free cash flow to approximately $800 million.
STERIS plc director Mohsen Sohi exercised a fully vested option to purchase 3,781 ordinary shares at $71.40 per share, an award originally received in connection with the company’s 2019 redomiciliation. In a net cashless exercise, options relating to 1,837 shares were surrendered to pay the option price. After these transactions, he directly owned 24,305 ordinary shares. The filing indicates the transactions were not made under a Rule 10b5-1 trading plan.
STERIS plc senior vice president, general counsel and secretary John Adam Zangerle reported an open-market sale of 1,419 Ordinary Shares at $209.28 per share. After this transaction, he directly holds 35,259 Ordinary Shares.
As of June 15, 2026, 8,239 of these Ordinary Shares are restricted, with restrictions scheduled to lapse in stages between June 2, 2027 and June 4, 2029.
STERIS plc reported Form 144 resale notices for restricted stock lapses. The filing lists restricted stock lapses tied to equity compensation: 820 shares dated 06/01/2026 and 599 shares dated 06/02/2026. The entries appear under "Securities To Be Sold."
STERIS plc is asking shareholders to vote at its July 31, 2026 annual general meeting in Dublin on eight proposals, including electing nine directors, ratifying Ernst & Young as auditors, an advisory say-on-pay vote, and renewing authorities to issue shares and opt out of Irish pre-emption rights.
The proxy highlights a record fiscal 2026, with revenue up 8.7% to $5,935.9 million and net income rising to $782.3 million, or $7.93 per diluted share. Adjusted net income reached $1,003.4 million, or $10.17 per diluted share, and free cash flow grew 24.9% to $982.9 million. Operating cash flow increased 16.8% to $1,341.4 million.
The Board stresses strong governance practices, broad director independence, and a pay-for-performance philosophy. In fiscal 2026, 90.3% of CEO Daniel Carestio’s compensation was variable, with his annual incentive paying out $1,725,007, or 125.1% of target, based entirely on financial metrics. Shareholders of record at June 2, 2026, with 97,457,680 ordinary shares outstanding, are encouraged to vote by proxy.
STERIS plc senior executive reports routine tax withholding transaction. On June 4, 2026, Sr. VP and General Counsel John Adam Zangerle had 401 ordinary shares withheld at $212.24 per share to cover taxes on 1,376 restricted shares that vested that day, rather than selling shares in the market.
After this withholding, he directly holds 36,678 ordinary shares, including 8,239 restricted shares as of June 8, 2026. The remaining restricted shares are scheduled to lapse in stages through June 4, 2029, reflecting ongoing equity-based compensation.
STERIS plc reported that V.P. & Corporate Treasurer Renato Tamaro had 65 Ordinary Shares withheld on June 4, 2026 as a tax-withholding disposition tied to a restricted share vesting. The 65 shares came from 221 restricted shares that vested that day and were valued at the NYSE closing price on June 4, 2026. Following this withholding, Tamaro directly holds 6,194 Ordinary Shares, of which 1,405 remain restricted. These restrictions are scheduled to lapse in tranches between June 2, 2027 and June 4, 2029.